0001127602-20-009078.txt : 20200303
0001127602-20-009078.hdr.sgml : 20200303
20200303165331
ACCESSION NUMBER: 0001127602-20-009078
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bancel Stephane
CENTRAL INDEX KEY: 0001443340
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 20683295
MAIL ADDRESS:
STREET 1: 320 BENT STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-02-28
0001682852
Moderna, Inc.
MRNA
0001443340
Bancel Stephane
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
1
Chief Executive Officer
Common Stock
2020-02-28
4
S
0
3674
22.78
D
725378
I
See Footnote
Common Stock
2020-02-28
4
S
0
5463
23.48
D
719915
I
See Footnote
Common Stock
2020-02-28
4
S
0
459
25.65
D
719456
I
See Footnote
Common Stock
2020-02-28
4
S
0
1450
24.36
D
718006
I
See Footnote
Common Stock
2020-03-02
4
S
0
3857
27.09
D
6718791
D
Common Stock
2020-03-02
4
S
0
7713
27.09
D
7945503
I
See Footnote
Common Stock
2020-03-02
4
S
0
3857
27.09
D
9229029
I
See Footnote
Stock Option (Right to Buy)
25.93
2020-02-28
4
A
0
644480
0
A
2021-02-28
2030-02-28
Common Stock
644480
644480
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.09 to $23.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.31 to $25.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.15 to $24.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
This sale was effected pursuant to a Rule 10b5-1 trading plan.
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ Lori Henderson, as Attorney-in-Fact
2020-03-03